(Q42695854)

5 November 2017

title

Pharmacokinetics of nateglinide in renally impaired diabetic patients (English)

1 reference

5 November 2017

1 reference

Damayanthi Devineni

1

1 reference

5 November 2017

Yulia H Walter

2

1 reference

5 November 2017

Harold T Smith

3

1 reference

5 November 2017

James S Lee

4

1 reference

5 November 2017

Pratapa Prasad

5

1 reference

5 November 2017

James F McLeod

6

1 reference

5 November 2017

publication date

1 February 2003

1 reference

The Journal of Clinical Pharmacology

5 November 2017

published in

1 reference

5 November 2017

volume

43

1 reference

5 November 2017

issue

2

1 reference

5 November 2017

page(s)

163-170

1 reference

Comparability of the different registries on renal replacement therapy

5 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270002239825

High incidence of diabetic nephropathy in early-onset Japanese NIDDM patients. Risk analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002239825

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002239825

Glucose control guidelines: current concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002239825

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002239825

Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002239825

The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002239825

Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002239825

Renal scanning 99mTc diethylene-triamine pentaacetic acid glomerular filtration rate (GFR) determination compared with iothalamate clearance GFR in diabetics. The Collaborative Study Group for The study of Angiotensin-Converting Enzyme Inhibition in

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002239825

Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002239825

Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002239825

Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002239825

Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002239825

Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002239825

Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270002239825

21 January 2018

Identifiers

DOI

10.1177/0091270002239825

1 reference

5 November 2017

1 reference